Article info
PDFPostScript
Letter
Sustained disability improvement is associated with T1 lesion volume shrinkage in natalizumab-treated patients with multiple sclerosis
- Correspondence to Dr Luca Prosperini, Department of Neurology and Psychiatry, Sapienza University, Viale dell'Università, Rome 30-00185, Italy; luca.prosperini{at}uniroma1.it
Citation
Sustained disability improvement is associated with T1 lesion volume shrinkage in natalizumab-treated patients with multiple sclerosis
Publication history
- Received February 3, 2014
- Revised March 26, 2014
- Accepted April 5, 2014
- First published April 30, 2014.
Online issue publication
April 13, 2016
Article Versions
- Previous version (13 April 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions